CSS
ALGS icon

Cubist Systematic Strategies’s Aligos Therapeutics ALGS Stock Holding History

Cubist Systematic Strategies’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-532
Closed -$11.6K – 3438
2023
Q1 		$11.6K Buy
+532
New +$20.3K ﹤0.01% 3713
2022
Q4 		– Sell
-1
Closed -$25 – 4184
2022
Q3 		$0 Sell
1
-153
-99% -$5.08K ﹤0.01% 4396
2022
Q2 		$5K Sell
154
-63
-29% -$2.14K ﹤0.01% 4296
2022
Q1 		$12K Buy
217
+16
+8% +$1.28K ﹤0.01% 3491
2021
Q4 		$60K Buy
+201
New +$73.3K ﹤0.01% 3284

Other funds holding ALGS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Cubist Systematic Strategies's ALGS Position: Q2 2023 in Review

Cubist Systematic Strategies sold out of Aligos Therapeutics (ALGS) in Q2 2023, closing a stake of 532 shares — an estimated $11.6K sold.

Cubist Systematic Strategies first reported a position in ALGS in Q4 2021 and held it in 5 quarters. The position peaked at $60K in Q4 2021. 41 funds tracked by Wall St. Rank hold ALGS as of Q2 2023.

  • Cubist Systematic Strategies reported no remaining Aligos Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Cubist Systematic Strategies sold 532 Aligos Therapeutics shares in Q2 2023, an estimated $11.6K.
  • Cubist Systematic Strategies first reported a position in Aligos Therapeutics in Q4 2021 and held it in 5 quarters.
  • Cubist Systematic Strategies's Aligos Therapeutics position peaked at $60K in Q4 2021.
  • 41 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2023.

Based on Cubist Systematic Strategies's 13F filing for Q2 2023, filed 14 Aug 2023.